Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Germaine C. Verwoert is active.

Publication


Featured researches published by Germaine C. Verwoert.


Nature Genetics | 2009

Genome-wide association study of blood pressure and hypertension

Daniel Levy; Georg B. Ehret; Kenneth Rice; Germaine C. Verwoert; Lenore J. Launer; Abbas Dehghan; Nicole L. Glazer; Alanna C. Morrison; Andrew D. Johnson; Thor Aspelund; Yurii S. Aulchenko; Thomas Lumley; Anna Köttgen; Fernando Rivadeneira; Gudny Eiriksdottir; Xiuqing Guo; Dan E. Arking; Gary F. Mitchell; Francesco Mattace-Raso; Albert V. Smith; Kent D. Taylor; Robert B. Scharpf; Shih Jen Hwang; Eric J.G. Sijbrands; Joshua C. Bis; Tamara B. Harris; Santhi K. Ganesh; Christopher J. O'Donnell; Albert Hofman; Jerome I. Rotter

Blood pressure is a major cardiovascular disease risk factor. To date, few variants associated with interindividual blood pressure variation have been identified and replicated. Here we report results of a genome-wide association study of systolic (SBP) and diastolic (DBP) blood pressure and hypertension in the CHARGE Consortium (n = 29,136), identifying 13 SNPs for SBP, 20 for DBP and 10 for hypertension at P < 4 × 10−7. The top ten loci for SBP and DBP were incorporated into a risk score; mean BP and prevalence of hypertension increased in relation to the number of risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-analysis with the Global BPgen Consortium (n = 34,433), four CHARGE loci attained genome-wide significance (P < 5 × 10−8) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1). Identifying genes associated with blood pressure advances our understanding of blood pressure regulation and highlights potential drug targets for the prevention or treatment of hypertension.


European Heart Journal | 2010

Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'Establishing normal and reference values'

Francesco Mattace-Raso; Albert Hofman; Germaine C. Verwoert; Jacqueline C. M. Witteman; Ian B. Wilkinson; John R. Cockcroft; Carmel M. McEniery; Yasmin; Stéphane Laurent; Pierre Boutouyrie; Erwan Bozec; Tine W. Hansen; Christian Torp-Pedersen; Hans Ibsen; Jørgen Jeppesen; Sebastian Vermeersch; Ernst Rietzschel; Marc De Buyzere; Thierry C. Gillebert; Luc M. Van Bortel; Patrick Segers; Charalambos Vlachopoulos; Constantinos Aznaouridis; Christodoulos Stefanadis; Athanase Benetos; Carlos Labat; Patrick Lacolley; Coen D. A. Stehouwer; Giel Nijpels; Jacqueline M. Dekker

Aims Carotid–femoral pulse wave velocity (PWV), a direct measure of aortic stiffness, has become increasingly important for total cardiovascular (CV) risk estimation. Its application as a routine tool for clinical patient evaluation has been hampered by the absence of reference values. The aim of the present study is to establish reference and normal values for PWV based on a large European population. Methods and results We gathered data from 16 867 subjects and patients from 13 different centres across eight European countries, in which PWV and basic clinical parameters were measured. Of these, 11 092 individuals were free from overt CV disease, non-diabetic and untreated by either anti-hypertensive or lipid-lowering drugs and constituted the reference value population, of which the subset with optimal/normal blood pressures (BPs) (n = 1455) is the normal value population. Prior to data pooling, PWV values were converted to a common standard using established conversion formulae. Subjects were categorized by age decade and further subdivided according to BP categories. Pulse wave velocity increased with age and BP category; the increase with age being more pronounced for higher BP categories and the increase with BP being more important for older subjects. The distribution of PWV with age and BP category is described and reference values for PWV are established. Normal values are proposed based on the PWV values observed in the non-hypertensive subpopulation who had no additional CV risk factors. Conclusion The present study is the first to establish reference and normal values for PWV, combining a sizeable European population after standardizing results for different methods of PWV measurement.


Nature Genetics | 2010

Genome-wide association study of PR interval

Arne Pfeufer; Charlotte van Noord; Kristin D. Marciante; Dan E. Arking; Martin G. Larson; Albert V. Smith; Kirill V. Tarasov; Martina Müller; Nona Sotoodehnia; Moritz F. Sinner; Germaine C. Verwoert; Man Li; W.H. Linda Kao; Anna Köttgen; Josef Coresh; Joshua C. Bis; Bruce M. Psaty; Kenneth Rice; Jerome I. Rotter; Fernando Rivadeneira; Albert Hofman; Jan A. Kors; Bruno H. Stricker; André G. Uitterlinden; Cornelia M. van Duijn; Britt M. Beckmann; Wiebke Sauter; Christian Gieger; Steven A. Lubitz; Christopher Newton-Cheh

The electrocardiographic PR interval (or PQ interval) reflects atrial and atrioventricular nodal conduction, disturbances of which increase risk of atrial fibrillation. We report a meta-analysis of genome-wide association studies for PR interval from seven population-based European studies in the CHARGE Consortium: AGES, ARIC, CHS, FHS, KORA, Rotterdam Study, and SardiNIA (N = 28,517). We identified nine loci associated with PR interval at P < 5 × 10−8. At the 3p22.2 locus, we observed two independent associations in voltage-gated sodium channel genes, SCN10A and SCN5A. Six of the loci were near cardiac developmental genes, including CAV1-CAV2, NKX2-5 (CSX1), SOX5, WNT11, MEIS1, and TBX5-TBX3, providing pathophysiologically interesting candidate genes. Five of the loci, SCN5A, SCN10A, NKX2-5, CAV1-CAV2, and SOX5, were also associated with atrial fibrillation (N = 5,741 cases, P < 0.0056). This suggests a role for common variation in ion channel and developmental genes in atrial and atrioventricular conduction as well as in susceptibility to atrial fibrillation.


Nature Genetics | 2009

Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium

Santhi K. Ganesh; Neil A. Zakai; Frank J. A. van Rooij; Nicole Soranzo; Albert V. Smith; Michael A. Nalls; Ming-Huei Chen; Anna Köttgen; Nicole L. Glazer; Abbas Dehghan; Brigitte Kühnel; Thor Aspelund; Qiong Yang; Toshiko Tanaka; Andrew E. Jaffe; Joshua C. Bis; Germaine C. Verwoert; Alexander Teumer; Caroline S. Fox; Jack M. Guralnik; Georg B. Ehret; Kenneth Rice; Janine F. Felix; Augusto Rendon; Gudny Eiriksdottir; Daniel Levy; Kushang V. Patel; Eric Boerwinkle; Jerome I. Rotter; Albert Hofman

Measurements of erythrocytes within the blood are important clinical traits and can indicate various hematological disorders. We report here genome-wide association studies (GWAS) for six erythrocyte traits, including hemoglobin concentration (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell count (RBC). We performed an initial GWAS in cohorts of the CHARGE Consortium totaling 24,167 individuals of European ancestry and replication in additional independent cohorts of the HaemGen Consortium totaling 9,456 individuals. We identified 23 loci significantly associated with these traits in a meta-analysis of the discovery and replication cohorts (combined P values ranging from 5 × 10−8 to 7 × 10−86). Our findings include loci previously associated with these traits (HBS1L-MYB, HFE, TMPRSS6, TFR2, SPTA1) as well as new associations (EPO, TFRC, SH2B3 and 15 other loci). This study has identified new determinants of erythrocyte traits, offering insight into common variants underlying variation in erythrocyte measures.


Annals of Internal Medicine | 2012

Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.

Maryam Kavousi; Suzette E. Elias-Smale; Joost H.W. Rutten; Maarten J.G. Leening; Rozemarijn Vliegenthart; Germaine C. Verwoert; Gabriel P. Krestin; Matthijs Oudkerk; Moniek P.M. de Maat; Frank W.G. Leebeek; Francesco Mattace-Raso; Jan Lindemans; Albert Hofman; Ewout W. Steyerberg; Aad van der Lugt; Anton H. van den Meiracker; Jacqueline C. M. Witteman

BACKGROUND Whether newer risk markers for coronary heart disease (CHD) improve CHD risk prediction remains unclear. OBJECTIVE To assess whether newer risk markers for CHD risk prediction and stratification improve Framingham risk score (FRS) predictions. DESIGN Prospective population-based study. SETTING The Rotterdam Study, Rotterdam, the Netherlands. PARTICIPANTS 5933 asymptomatic, community-dwelling participants (mean age, 69.1 years [SD, 8.5]). MEASUREMENTS Traditional CHD risk factors used in the FRS (age, sex, systolic blood pressure, treatment of hypertension, total and high-density lipoprotein cholesterol levels, smoking, and diabetes) and newer CHD risk factors (N-terminal fragment of prohormone B-type natriuretic peptide levels, von Willebrand factor antigen levels, fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive protein levels, homocysteine levels, uric acid levels, coronary artery calcium [CAC] scores, carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity). RESULTS Adding CAC scores to the FRS improved the accuracy of risk predictions (c-statistic increase, 0.05 [95% CI, 0.02 to 0.06]; net reclassification index, 19.3% overall [39.3% in those at intermediate risk, by FRS]). Levels of N-terminal fragment of prohormone B-type natriuretic peptide also improved risk predictions but to a lesser extent (c-statistic increase, 0.02 [CI, 0.01 to 0.04]; net reclassification index, 7.6% overall [33.0% in those at intermediate risk, by FRS]). Improvements in predictions with other newer markers were marginal. LIMITATION The findings may not be generalizable to younger or nonwhite populations. CONCLUSION Among 12 CHD risk markers, improvements in FRS predictions were most statistically and clinically significant with the addition of CAC scores. Further investigation is needed to assess whether risk refinements using CAC scores lead to a meaningful change in clinical outcome. Whether to use CAC score screening as a more routine test for risk prediction requires full consideration of the financial and clinical costs of performing versus not performing the test for both persons and health systems. PRIMARY FUNDING SOURCE Netherlands Organization for Health Research and Development (ZonMw).


Hypertension | 2011

Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals

Andrew D. Johnson; Christopher Newton-Cheh; Daniel I. Chasman; Georg Ehret; Toby Johnson; Lynda M. Rose; Kenneth Rice; Germaine C. Verwoert; Lenore J. Launer; Vilmundur Gudnason; Martin G. Larson; Aravinda Chakravarti; Bruce M. Psaty; Mark J. Caulfield; Cornelia M. van Duijn; Paul M. Ridker; Patricia B. Munroe; Daniel Levy

We previously conducted genome-wide association meta-analysis of systolic blood pressure, diastolic blood pressure, and hypertension in 29 136 people from 6 cohort studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Here we examine associations of these traits with 30 gene regions encoding known antihypertensive drug targets. We find nominal evidence of association of ADRB1, ADRB2, AGT, CACNA1A, CACNA1C, and SLC12A3 polymorphisms with 1 or more BP traits in the Cohorts for Heart and Aging Research in Genomic Epidemiology genome-wide association meta-analysis. We attempted replication of the top meta-analysis single nucleotide polymorphisms for these genes in the Global BPgen Consortium (n=34 433) and the Womens Genome Health Study (n=23 019) and found significant results for rs1801253 in ADRB1 (Arg389Gly), with the Gly allele associated with a lower mean systolic blood pressure (&bgr;: 0.57 mm Hg; SE: 0.09 mm Hg; meta-analysis: P=4.7×10−10), diastolic blood pressure (&bgr;: 0.36 mm Hg; SE: 0.06 mm Hg; meta-analysis: P=9.5×10−10), and prevalence of hypertension (&bgr;: 0.06 mm Hg; SE: 0.02 mm Hg; meta-analysis: P=3.3×10−4). Variation in AGT (rs2004776) was associated with systolic blood pressure (&bgr;: 0.42 mm Hg; SE: 0.09 mm Hg; meta-analysis: P=3.8×10−6), as well as diastolic blood pressure (P=5.0×10−8) and hypertension (P=3.7×10−7). A polymorphism in ACE (rs4305) showed modest replication of association with increased hypertension (&bgr;: 0.06 mm Hg; SE: 0.01 mm Hg; meta-analysis: P=3.0×10−5). Two loci, ADRB1 and AGT, contain single nucleotide polymorphisms that reached a genome-wide significance threshold in meta-analysis for the first time. Our findings suggest that these genes warrant further studies of their genetic effects on blood pressure, including pharmacogenetic interactions.


Journal of the American Geriatrics Society | 2008

Orthostatic Hypotension and Risk of Cardiovascular Disease in Elderly People: The Rotterdam Study

Germaine C. Verwoert; Francesco Mattace-Raso; Albert Hofman; Jan Heeringa; Bruno H. Stricker; Monique M.B. Breteler; Jacqueline C. M. Witteman

OBJECTIVES: To determine the prognostic role of orthostatic hypotension for cardiovascular disease (CVD) and all‐cause mortality in elderly people.


PLOS Genetics | 2010

Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six loci influencing serum magnesium levels

Tamra E. Meyer; Germaine C. Verwoert; Shih-Jen Hwang; Nicole L. Glazer; Albert V. Smith; Frank J. A. van Rooij; Georg B. Ehret; Eric Boerwinkle; Janine F. Felix; Tennille S. Leak; Tamara B. Harris; Qiong Yang; Abbas Dehghan; Thor Aspelund; Ronit Katz; Georg Homuth; Thomas Kocher; Rainer Rettig; Janina S. Ried; Christian Gieger; Hanna Prucha; Arne Pfeufer; Thomas Meitinger; Josef Coresh; Albert Hofman; Mark J. Sarnak; Yii-Der I. Chen; André G. Uitterlinden; Aravinda Chakravarti; Bruce M. Psaty

Magnesium, potassium, and sodium, cations commonly measured in serum, are involved in many physiological processes including energy metabolism, nerve and muscle function, signal transduction, and fluid and blood pressure regulation. To evaluate the contribution of common genetic variation to normal physiologic variation in serum concentrations of these cations, we conducted genome-wide association studies of serum magnesium, potassium, and sodium concentrations using ∼2.5 million genotyped and imputed common single nucleotide polymorphisms (SNPs) in 15,366 participants of European descent from the international CHARGE Consortium. Study-specific results were combined using fixed-effects inverse-variance weighted meta-analysis. SNPs demonstrating genome-wide significant (p<5×10−8) or suggestive associations (p<4×10−7) were evaluated for replication in an additional 8,463 subjects of European descent. The association of common variants at six genomic regions (in or near MUC1, ATP2B1, DCDC5, TRPM6, SHROOM3, and MDS1) with serum magnesium levels was genome-wide significant when meta-analyzed with the replication dataset. All initially significant SNPs from the CHARGE Consortium showed nominal association with clinically defined hypomagnesemia, two showed association with kidney function, two with bone mineral density, and one of these also associated with fasting glucose levels. Common variants in CNNM2, a magnesium transporter studied only in model systems to date, as well as in CNNM3 and CNNM4, were also associated with magnesium concentrations in this study. We observed no associations with serum sodium or potassium levels exceeding p<4×10−7. Follow-up studies of newly implicated genomic loci may provide additional insights into the regulation and homeostasis of human serum magnesium levels.


Stroke | 2012

Arterial Stiffness and Cerebral Small Vessel Disease: The Rotterdam Scan Study

Mariëlle Poels; Keren Zaccai; Germaine C. Verwoert; Meike W. Vernooij; Albert Hofman; Aad van der Lugt; Jacqueline C. M. Witteman; Monique M.B. Breteler; Francesco Mattace-Raso; M. Arfan Ikram

Background and Purpose— Aging and vascular risk factors contribute to arterial stiffening. Increased arterial stiffness exposes the small vessels in the brain to abnormal flow pulsations and, as such, may contribute to the pathogenesis of cerebral small vessel disease. In a population-based study, we investigated the association between arterial stiffness, as measured by aortic pulse wave velocity (aPWV), and small vessel disease. Methods— Overall, 1460 participants (mean age, 58.2 years) underwent aPWV measurement and brain MRI scanning. We calculated aPWV by measuring time differences and distances between pulse waves in the carotid and femoral arteries. Using automated MRI analysis, we obtained white matter lesion volumes. Infarcts and microbleeds were rated visually. We used linear and logistic regression models to associate aPWV with small vessel disease, adjusting for age, sex, mean arterial pressure, and heart rate and additionally for cardiovascular risk factors. Subsequently, we explored associations in strata of hypertension. Results— In the study group, higher aPWV was associated with larger white matter lesion volume (difference in volume per SD increase in aPWV 0.07; 95% CI, 0.02–0.12) but not with lacunar infarcts or microbleeds. In persons with uncontrolled hypertension, higher aPWV was significantly associated with larger white matter lesion volume (difference in volume per SD increase in aPWV 0.09; 95% CI, 0.00–0.18), deep or infratentorial microbleeds (OR, 2.13; 95% CI, 1.16–3.91), and to a lesser extent also with lacunar infarcts (OR, 1.63; 95% CI, 0.98–2.70). No such associations were present in persons with controlled hypertension or without hypertension. Conclusions— In our study, increased arterial stiffness is associated with a larger volume of white matter lesions.


Molecular Psychiatry | 2012

Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM

Najaf Amin; Enda M. Byrne; Julie Johnson; Georgia Chenevix-Trench; Stefan Walter; Ilja M. Nolte; J. M. Vink; R. Rawal; Massimo Mangino; A. Teumer; J. C. Keers; Germaine C. Verwoert; S. Baumeister; Reiner Biffar; Astrid Petersmann; N. Dahmen; A. Doering; Aaron Isaacs; Linda Broer; Naomi R. Wray; Grant W. Montgomery; Daniel Levy; Bruce M. Psaty; V. Gudnason; Aravinda Chakravarti; P. Sulem; D. F. Gudbjartsson; Lambertus A. Kiemeney; U. Thorsteinsdottir; K. Stefansson

Coffee consumption is a model for addictive behavior. We performed a meta-analysis of genome-wide association studies (GWASs) on coffee intake from 8 Caucasian cohorts (N=18 176) and sought replication of our top findings in a further 7929 individuals. We also performed a gene expression analysis treating different cell lines with caffeine. Genome-wide significant association was observed for two single-nucleotide polymorphisms (SNPs) in the 15q24 region. The two SNPs rs2470893 and rs2472297 (P-values=1.6 × 10−11 and 2.7 × 10−11), which were also in strong linkage disequilibrium (r2=0.7) with each other, lie in the 23-kb long commonly shared 5′ flanking region between CYP1A1 and CYP1A2 genes. CYP1A1 was found to be downregulated in lymphoblastoid cell lines treated with caffeine. CYP1A1 is known to metabolize polycyclic aromatic hydrocarbons, which are important constituents of coffee, whereas CYP1A2 is involved in the primary metabolism of caffeine. Significant evidence of association was also detected at rs382140 (P-value=3.9 × 10−09) near NRCAM—a gene implicated in vulnerability to addiction, and at another independent hit rs6495122 (P-value=7.1 × 10−09)—an SNP associated with blood pressure—in the 15q24 region near the gene ULK3, in the meta-analysis of discovery and replication cohorts. Our results from GWASs and expression analysis also strongly implicate CAB39L in coffee drinking. Pathway analysis of differentially expressed genes revealed significantly enriched ubiquitin proteasome (P-value=2.2 × 10−05) and Parkinsons disease pathways (P-value=3.6 × 10−05).

Collaboration


Dive into the Germaine C. Verwoert's collaboration.

Top Co-Authors

Avatar

Albert Hofman

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gary F. Mitchell

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Aad van der Lugt

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Meike W. Vernooij

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Oscar H. Franco

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Kirill V. Tarasov

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge